Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Finished Goods (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Finished Goods for 12 consecutive years, with $51.5 million as the latest value for Q3 2022.

  • On a quarterly basis, Finished Goods fell 4.14% to $51.5 million in Q3 2022 year-over-year; TTM through Jul 2022 was $51.5 million, a 4.14% decrease, with the full-year FY2022 number at $58.5 million, up 12.54% from a year prior.
  • Finished Goods was $51.5 million for Q3 2022 at Usana Health Sciences, down from $57.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $58.5 million in Q1 2022 to a low of $36.6 million in Q1 2020.
  • A 5-year average of $47.8 million and a median of $48.7 million in 2018 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: soared 42.23% in 2018, then plummeted 30.13% in 2020.
  • Usana Health Sciences' Finished Goods stood at $48.0 million in 2018, then decreased by 14.69% to $40.9 million in 2019, then rose by 15.12% to $47.1 million in 2020, then grew by 16.78% to $55.0 million in 2021, then dropped by 6.3% to $51.5 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Finished Goods are $51.5 million (Q3 2022), $57.3 million (Q2 2022), and $58.5 million (Q1 2022).